Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 69Carcinoma, Non-Small-Cell Lung 62Stomach Neoplasms 32Prostatic Neoplasms 21Nasopharyngeal Carcinoma 20Lung Neoplasms 20Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Neoplasm Metastasis 8Head and Neck Neoplasms 7Inflammatory Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5HER2-positive Breast Cancer 5Adenocarcinoma 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4NSCLC 4Carcinoma, Squamous Cell 4Sarcoma 3Nasopharyngeal Neoplasms 3Hypopharyngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Ovarian Epithelial 3Breast Diseases 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Squamous Cell Lung Cancer 2

Interventions

camrelizumab 2apatinib 2S 1 (combination) 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Metastatic Gastric Adenocarcinoma × Docetaxel × Clear all
NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡